# Evaluate the Safety and Efficacy of AD-35 Tablet in Subjects With Mild to Moderate Alzheimer's Disease

> **NCT03790982** · PHASE2 · UNKNOWN · sponsor: **Zhejiang Hisun Pharmaceutical Co. Ltd.** · enrollment: 240 (estimated)

## Conditions studied

- Alzheimer's Disease

## Interventions

- **DRUG:** Placebo of AD-35 60mg /AD-35 30mg
- **DRUG:** Placebo of AD-35 60mg /AD-35 60mg
- **DRUG:** AD-35 30 mg + Placebo of AD-35 30 mg
- **DRUG:** AD-35 60 mg

## Key facts

- **NCT ID:** NCT03790982
- **Lead sponsor:** Zhejiang Hisun Pharmaceutical Co. Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2018-12-01
- **Primary completion:** 2020-12-30
- **Final completion:** 2021-07-30
- **Target enrollment:** 240 (ESTIMATED)
- **Last updated:** 2019-01-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03790982

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03790982, "Evaluate the Safety and Efficacy of AD-35 Tablet in Subjects With Mild to Moderate Alzheimer's Disease". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT03790982. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*